Brief: Compugen's COM701(Anti-PVRIG)In Dual And Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity And Immune Activation In Patients With Platinum Resistant Ovarian Cancer
06/12/2022 12:51
Dec 6 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN'S COM701 (ANTI-PVRIG) IN DUAL AND TRIPLE
COMBINATION
DEMONSTRATES PRELIMINARY DURABLE ANTI-TUMOR ACTIVITY AND IMMUNE
ACTIVATION IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
Source text for Eikon: ID:nPn6TRQ3Ka
Further company coverage: CGEN.TA
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025